- Home
- AACB vs NGNE Comparison
AACB vs NGNE Comparison
Compare AACB & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AACB | NGNE |
|---|---|---|
| Founded | 2024 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.9M | 327.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | AACB | NGNE |
|---|---|---|
| Price | $10.44 | $27.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $63.57 |
| AVG Volume (30 Days) | 45.5K | ★ 132.7K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.04 | $14.65 |
| 52 Week High | $10.44 | $37.27 |
Technical Indicators
Market Signals| Indicator | AACB | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 72.25 | 50.45 |
| Support Level | $10.10 | $18.25 |
| Resistance Level | N/A | $29.05 |
| Average True Range (ATR) | 0.01 | 2.39 |
| MACD | 0.00 | -0.65 |
| Stochastic Oscillator | 100.00 | 21.07 |
Price Performance
Historical ComparisonAbout AACB Artius II Acquisition Inc. Class A Ordinary Shares
Artius II Acquisition Inc is a blank check company.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.